{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:42:09Z","timestamp":1789882929144,"version":"4.0.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T00:00:00Z","timestamp":1537747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM107495"],"award-info":[{"award-number":["R01GM107495"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R21AA025750"],"award-info":[{"award-number":["R21AA025750"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0204041","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T17:31:21Z","timestamp":1537810281000},"page":"e0204041","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Partial agonist activity of \u03b11-adrenergic receptor antagonists for chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3"],"prefix":"10.1371","volume":"13","author":[{"given":"Xianlong","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Abdelkarim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren J.","family":"Albee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Volkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Gaponenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-0887","authenticated-orcid":true,"given":"Matthias","family":"Majetschak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,9,24]]},"reference":[{"issue":"9","key":"ref1","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1097\/HJH.0b013e32833b912c","article-title":"Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?","volume":"28","author":"N Chapman","year":"2010","journal-title":"J Hypertens"},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17081339","article-title":"The Role of alpha1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers","volume":"17","author":"M Batty","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00053426","article-title":"Pathogenesis and treatment of Raynaud's phenomenon","volume":"4","author":"JD Coffman","year":"1990","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1507598","article-title":"Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans","volume":"378","author":"MA Raskind","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/pros.23167","article-title":"Relative cytotoxic potencies and cell death mechanisms of alpha1 -adrenoceptor antagonists in prostate cancer cell lines","volume":"76","author":"A Forbes","year":"2016","journal-title":"Prostate"},{"issue":"2","key":"ref6","first-page":"597","article-title":"Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action","volume":"62","author":"CM Benning","year":"2002","journal-title":"Cancer Res"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006575","article-title":"alpha1-Adrenergic Receptors Function Within Hetero-Oligomeric Complexes With Atypical Chemokine Receptor 3 and Chemokine (C-X-C motif) Receptor 4 in Vascular Smooth Muscle Cells","volume":"6","author":"LJ Albee","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"ref8","article-title":"New Insights into Mechanisms and Functions of Chemokine (C-X-C Motif) Receptor 4 Heteromerization in Vascular Smooth Muscle","volume":"17","author":"AE Evans","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"13","key":"ref9","doi-asserted-by":"crossref","first-page":"E1659","DOI":"10.1073\/pnas.1417564112","article-title":"Heteromerization of chemokine (C-X-C motif) receptor 4 with alpha1A\/B-adrenergic receptors controls alpha1-adrenergic receptor function","volume":"112","author":"A Tripathi","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1038\/s41598-018-21096-4","article-title":"Asymmetrical ligand-induced cross-regulation of chemokine (C-X-C motif) receptor 4 by alpha1-adrenergic receptors at the heteromeric receptor complex","volume":"8","author":"X Gao","year":"2018","journal-title":"Scientific reports"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nsmb.3014","article-title":"PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome","volume":"22","author":"WK Kroeze","year":"2015","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.170207","article-title":"Identification and functional characterization of arginine vasopressin receptor 1A: atypical chemokine receptor 3 heteromers in vascular smooth muscle","volume":"8","author":"LJ Albee","year":"2018","journal-title":"Open Biol"},{"issue":"1\u20132","key":"ref13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11010-017-3044-7","article-title":"Functional and structural consequences of chemokine (C-X-C motif) receptor 4 activation with cognate and non-cognate agonists","volume":"434","author":"JM Eby","year":"2017","journal-title":"Mol Cell Biochem"},{"issue":"38","key":"ref14","doi-asserted-by":"crossref","first-page":"33466","DOI":"10.1074\/jbc.M111.233742","article-title":"The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1alpha function through distinct receptor interactions","volume":"286","author":"V Saini","year":"2011","journal-title":"J Biol Chem"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10858-009-9306-2","article-title":"Differences in lysine pKa values may be used to improve NMR signal dispersion in reductively methylated proteins","volume":"43","author":"SJ Abraham","year":"2009","journal-title":"J Biomol NMR"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00197809","article-title":"NMRPipe: a multidimensional spectral processing system based on UNIX pipes","volume":"6","author":"F Delaglio","year":"1995","journal-title":"J Biomol NMR"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"e0187949","DOI":"10.1371\/journal.pone.0187949","article-title":"Effects of cognate, non-cognate and synthetic CXCR4 and ACKR3 ligands on human lung endothelial cell barrier function","volume":"12","author":"YH Cheng","year":"2017","journal-title":"PLoS One"},{"issue":"50","key":"ref18","doi-asserted-by":"crossref","first-page":"E5363","DOI":"10.1073\/pnas.1417037111","article-title":"Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: molecular modeling and experimental validation","volume":"111","author":"I Kufareva","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"ref19","doi-asserted-by":"crossref","first-page":"15566","DOI":"10.1074\/jbc.M110.103408","article-title":"CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin","volume":"285","author":"V Saini","year":"2010","journal-title":"J Biol Chem"},{"issue":"49","key":"ref20","doi-asserted-by":"crossref","first-page":"37939","DOI":"10.1074\/jbc.C110.147470","article-title":"The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains","volume":"285","author":"S Gravel","year":"2010","journal-title":"The Journal of biological chemistry"},{"issue":"34","key":"ref21","doi-asserted-by":"crossref","first-page":"35518","DOI":"10.1074\/jbc.M405878200","article-title":"Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor","volume":"279","author":"S Ahn","year":"2004","journal-title":"J Biol Chem"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.bbamem.2006.11.002","article-title":"Regulation of CXCR4 signaling","volume":"1768","author":"JM Busillo","year":"2007","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"ref23","first-page":"628","article-title":"Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proceedings of the National Academy of Sciences of the United States of America","volume":"107","author":"S Rajagopal","year":"2010"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1124\/mol.108.053389","article-title":"AMD3100 is a CXCR7 ligand with allosteric agonist properties","volume":"75","author":"I Kalatskaya","year":"2009","journal-title":"Molecular pharmacology"},{"issue":"21","key":"ref25","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1111\/bph.12813","article-title":"Pharmacologically distinct phenotypes of alpha1B -adrenoceptors: variation in binding and functional affinities for antagonists","volume":"171","author":"H Yoshiki","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1074\/jbc.M114.631119","article-title":"Angiotensin II type I and prostaglandin F2alpha receptors cooperatively modulate signaling in vascular smooth muscle cells","volume":"290","author":"E Goupil","year":"2015","journal-title":"J Biol Chem"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/01.HYP.4.1.93","article-title":"Prazosin plasma concentration and blood pressure reduction","volume":"4","author":"P Larochelle","year":"1982","journal-title":"Hypertension"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.juro.2007.06.043","article-title":"Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study","volume":"178","author":"AM Harris","year":"2007","journal-title":"J Urol"},{"issue":"2","key":"ref29","first-page":"253","article-title":"Decreased risk of bladder cancer in men treated with quinazoline-based alpha1-adrenoceptor antagonists","volume":"12","author":"FM Martin","year":"2008","journal-title":"Gene Ther Mol Biol"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/iju.12156","article-title":"Reduction of prostate cancer incidence by naftopidil, an alpha1 -adrenoceptor antagonist and transforming growth factor-beta signaling inhibitor","volume":"20","author":"D Yamada","year":"2013","journal-title":"Int J Urol"},{"issue":"11","key":"ref31","first-page":"4695","article-title":"Therapeutic value of quinazoline-based compounds in prostate cancer","volume":"33","author":"J Bilbro","year":"2013","journal-title":"Anticancer Res"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10147-017-1187-x","article-title":"Biological\/pathological functions of the CXCL12\/CXCR4\/CXCR7 axes in the pathogenesis of bladder cancer","volume":"22","author":"A Nazari","year":"2017","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"ref33","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1074\/jbc.M707465200","article-title":"The role of CXCR7\/RDC1 as a chemokine receptor for CXCL12\/SDF-1 in prostate cancer","volume":"283","author":"J Wang","year":"2008","journal-title":"J Biol Chem"},{"issue":"18","key":"ref34","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1158\/0008-5472.CAN-17-0284","article-title":"Proinflammatory CXCL12-CXCR4\/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice","volume":"77","author":"A Saha","year":"2017","journal-title":"Cancer Res"},{"issue":"19","key":"ref35","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1158\/1078-0432.CCR-14-0914","article-title":"Molecular Pathways: Targeting the CXCR4-CXCL12 Axis\u2014Untapped Potential in the Tumor Microenvironment","volume":"21","author":"S. Scala","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/thno.5376","article-title":"Small molecule inhibitors of CXCR4","volume":"3","author":"B Debnath","year":"2013","journal-title":"Theranostics"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0204041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T19:36:21Z","timestamp":1571945781000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0204041"}},"subtitle":[],"editor":[{"given":"Raghavan","family":"Raju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,9,24]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0204041","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,24]]}}}